Literature DB >> 1531614

Ticlopidine and severe aplastic anaemia.

R Mataix1, E Ojeda, M C Perez, S Jimenez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1531614     DOI： 10.1111/j.1365-2141.1992.tb06412.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.

Authors:  F L Paradiso-Hardy; C M Angelo; K L Lanctôt; E A Cohen
Journal:  CMAJ       Date:  2000-11-28       Impact factor: 8.262

2.  Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4.

Authors:  Jyothi C Talakad; Manish B Shah; Gregory S Walker; Cathie Xiang; James R Halpert; Deepak Dalvie
Journal:  Drug Metab Dispos       Date:  2010-12-14       Impact factor: 3.922

Review 3.  Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke.

Authors:  S Noble; K L Goa
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

Review 4.  Clinical pharmacokinetics of ticlopidine.

Authors:  J P Desager
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

5.  A new model of busulphan-induced chronic bone marrow aplasia in the female BALB/c mouse.

Authors:  Frances M Gibson; C Michael Andrews; Paraskevi Diamanti; Sian Rizzo; George Macharia; Edward C Gordon-Smith; Thomas Williams; John Turton
Journal:  Int J Exp Pathol       Date:  2003-02       Impact factor: 1.925

6.  Ticlopidine hydrochloride use and threatened stroke.

Authors:  J F Rothrock; R G Hart
Journal:  West J Med       Date:  1994-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.